A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma

P
Patrick Loehrer, MD

Primary Investigator

Overview

This study is being done to test if treatment with both cabozantinib and erlotinib has an effect on pancreatic cancer.

Description

The purpose of this study is to look at a novel combination of targeted agents in a biomarker-selected population of patients with pancreatic cancer.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    pancreatic cancer
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must have:

  • a biopsy-proven diagnosis of adenocarcinoma of the pancreas (or recurrence of previously resected disease) with metastatic disease that is measurable per RECIST 1.1
  • The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

For a full list of participation criteria, please visit ClinicalTrials.gov


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1705697788 (IUSCC-0597)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center